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[57] ABSTRACT 
A method and preparation are described for treating 
human skin with retinoic acid glucuronide (RAG) in a 
topical carrier. For treatment of acne or wrinkled skin, 
RAG can be applied in an effective amount which is 
nonirritating to the skin. Retinoid dermatitis, an objec 
tionable side effect of topical application of retinoid 
compounds, can thereby be avoided. 
13 Claims, No Drawings 
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RETINOIC ACID GLUCURONIDE 
PREPARATIONS FOR APPLICATION TO THE 
SKIN 
GRANT REFERENCES 
Research relating to the present invention was sup 
ported in part by grants from the United States Govern 
ment; namely, USDA Grant 87-CRCR-1~2320 and NIH 
Grants DK32793 and DK39733. 
RELATED APPLICATION 
This application is a continuation-impart of co-pend 
ing application Ser. No. 07/355,778, ?led May 22, 1989, 
now abandoned. 
FIELD OF INVENTION 
The ?eld of this invention is the topical application of 
vitamin A and derivatives thereof for treatment of skin 
conditions such as acne and skin aging. 
BACKGROUND OF INVENTION 
Vitamin A and most derivatives thereof having vita 
min A activity are water-insoluble, being hydrophobic, 
lipid-soluble compounds. For example, neither retinoic 
acid nor retinol are water-soluble. It is known, how 
ever, that the glucuronide and glucose derivatives of 
retinoic acid and retinol are water-soluble. [See, for 
example, Lippel and Olson, J. Lipid. Res. 9:580-586 
(1968); Takabayashi, et al., Chem. Abs. 73:698342 (1970); 
Barua, et al., Amer J. Clin. Nutr-., 43:481-485 (1986).] 
Water-soluble glycoside derivatives of vitamin A are 
described in US. Pat. No. 4,457,918. The retinoic acid 
glucuronide and retinol glucuronide have been tested 
for effects in vitro on cultures of HL-60 cells (a continu 
ous human myeloid cell line): Zile, et al., Proc. Nat. 
Acad. Sci USA, 84:2208-2212 1987); and Gallup, et al., 
First Mid-America Molecular Biol. Colloquium, p. 36, 
Oct. 1986; and Zile Biol & Med, 186:269-274 (1987). 
Under the conditions of the HL-6O system assay, activ 
ity similar to retinoic acid and retinol was reported. 
Both Gallup, et al. and Zile, et al. found that retinoyl 
B-D-glucuronide (retinoic acid glucuronide) was at 
least 6-fold less cytotoxic to HL-60 cells than all-trans 
retinoic acid. 
The all-trans form of retinoic acid has been named 
tretinoin. Cream, gel and liquid preparations containing 
tretinoin have been approved in the United States for 
treatment of acne. These preparations are being mar 
lteted under the trademark “Retin-A” by the Dermato 
logical Division of Ortho Pharmaceutical Corporation, 
Raritan, NJ. Presently available strengths of “Retin-A” 
on a weight percent basis are 0.025% or 0.01% for the 
gel, 0.1% or 0.05% for the cream, and 0.05% for the 
liquid. Other potential uses for topical tretinoin have 
been reported, including treatment of aging skin (W eiss, 
et al., J. Amer. Acad. Dermal. 19:169-175, 1988), and 
treatment of xerophthalmia and corneal epithelial 
wounds (Ubels, et al., Current Eve Research, 
4:1049-1057 1985). 
Topical tretinoin is being experimentally tested for 
treatment of aging skin. It has been found, however, 
that the patients under treatment may experience local 
erythema and peeling of the skin, as has been observed 
in acne treatment. The degree of irritation varies with 
the strength of the preparation and the frequency of its 
application, higher concentrations and more frequent 









tion side effects. When such side effects are noted, the 
treatment can be discontinued for a number of days, a 
preparation of lower strength used, or the time between 
applications can be increased. In view of the clinically 
beneficial results obtained in the treatment of acne and 
the promising results with respect to improving the 
condition of aging skin, it would be desirable to utilize 
a less irritating form of retinoic acid. 
Weiss, et al. (1988), cited above, reported a double 
blind study con?rming earlier published reports that 
treatment with tretinoin is capable of at least partly 
reversing structural damage associated with extrinsic 
aging (photoaging) of the skin. I order to minimize skin 
irritation, Weiss et al. started treatment with 0.1% treti 
noin cream on a daily basis, and then advanced the 
patients to twice-a-day applications. When a patient was 
unable to tolerate the 0.1% cream, the patient was 
switched to a 0.05% cream. Most patients were able to 
continue with the treatments. However, during the 
course of their study Weiss, et al. found that “more than 
90% of the patients experienced some degree of derma 
titis in the tretinoin treated areas” (page 172, col. 1). The 
areas of the skin found most susceptible to retinoid 
dermatitis were the sides of the neck, the V-area of the 
neck and chest, the ventral arms, and the antecubital 
fossae. 
SUMMARY OF INVENTION 
This invention relates to topical medicaments for 
appliwtion to the epithelium. In speci?c embodiments, 
it relates to topical medicaments for application to the 
skin for treatment of acne and/or skin aging. The topi 
cal medicaments of this invention use a speci?c water 
soluble vitamin A derivative in admixture with spread 
able topical caIiers, such as gels, creams, liquid prepa 
rations such as lotions. 
The active therapeutic agent for use in the medica 
ments and treating methods of this invention is retinoic 
acid glucuronide. This compound is preferably in the 
all-trans form, but it may also be used in the l3-cis form. 
The topical medicaments of this invention preferably 
utilize carriers which contain an aqueous or polar sol 
vent phase so that the water-soluble vitamin A deriva 
tives can be dissolved therein. 
Unlike the retinoic acid preparations currently in 
commercial and clinical use, the preparations of this 
invention are not irritating to the skin. Not only does 
the glucuronide moiety provide water-solubility, but it 
also appreciably reduces side effects which can result in 
skin redness, scaling, and the like. Since the prepara 
tions of this invention are' not irritating to the skin, they 
can be applied to the skin at higher concentrations, 
and/or more frequent applications can be used. Either 
procedure ca increase the effectiveness of treatments 
for acne or skin aging. 
DETAILED DESCRIPTION 
The water-soluble vitamin A derivatives used in the 
preparations and methods of this invention are not 
available commercially, but they can be prepared from 
commercially available starting materials. These materi 
als include retinoic acid and retinyl acetate, which can 
be obtained from commercial sources in all-trans or 
l3-cis forms, for example, from‘ Sigma Chemical Co., St. 
Louis, Mo. D-glucuronic acid is also available commer 
cially, for example, from Aldrich Chemical Co., Mil 
waukee, Wis. 
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Retinoyl ?uoride is a useful intermediate for prepar 
ing retinoic acid glucuronide also called retinoyl B 
glucuronide. A method for preparing all-trans or l3-cis 
retinoyl ?uoride is described in Barua and Olson, Bio 
chimica. et Biophysica Acta, 757:288-299 (1983); and 
U.S. Pat. No. 4,473,503. A two-step process for prepar 
ing retinoic acid glucuronide from retinoyl ?uoride is 
described in Barua and Olson, J. Lipid. Res, 26:258-261 
(1985). Retinoyl ?uoride is ?rst reacted with 6,3 
glucuronolactone to produce 6,3-lactone of retinoyl 
glucuronic acid, which is then hydrolyzed with dilute 
alkali to give the retinoyl B-glucuronide. A one-step 
process for this synthesis is described in U.S. Pat. No. 
4,855,463. The reaction is carried out in an acetone 
water mixture proportioned so that both the water 
insoluble retinoyl ?uoride and the water-soluble glucu 
ronic acid are maintained in solution. 
The preparations of this invention can be formulated 
as ointments or lotions. The preparations preferably 
contain a polar or aqueous phase in which the active 
agent is dissolved. For example, aqueous gels can be 
used as an ointment base, and liquid preparations can be 
formulated as aqueous solutions, or with a polar solvent 
such as glycerol. Alternatively, however, an ointment 
can be formed from a lipid-base cream. The vitamin A 
compounds are soluble in polar organic solvents, such 
as glycerol, and can be formulated therein. Glycerol 
solutions of the compounds can be combined with gels, 
creams, or liquid preparations. 
Suitable water-soluble ointment bases include poly 
ethylene glycol. Emollients may be included and also 
preservatives, such as the parabens. More complex topi 
cal carrier formulations can also be used. For example, 
a gel vehicle may consist of butylated hydroxytoluene, 
hydroxypropyl cellulose, and ethanol. A cream vehicle 
may consist of a mixture of stearic acid, isopropyl my 
ristate, polyoxylstearate, stearyl alcohol, xanthan gum, 
sorbic acid, butylated hydroxytoluene, and water. A 
liquid vehicle may be composed of a mixture of polyeth 
ylene glycol, butylated hydroxytoluene, and ethanol. A 
topical vehicle for tretinoin and isotretinoin is described 
in U.S. Pat. No. 4,727,088. This vehicle, which contains 
long chain fatty alcohols and a volatile silicone, can be 
used with the therapeutic agent of this invention. 
Retinoic acid glucuronide ca be combined with the 
topical cam'er (ointment or liquid) in a wider range of 
strengths than has heretofore been available for retinoic 
acid preparations. For example, the preparations may 
be formulated to contain from 0.02 to 0.5 weight per 
cent of the active agent. On the basis of present informa 
tion, it is believed that the most useful formulations will 
contain from 0.05 to 0.35% by weight of retinoic acid 
glucuronide. To maximize therapeutic effect, prepara 
tions may need to contain more than 0.15% of the active 
agent, such as 0.2% up to 0.5% by weight. 
It will be understood that the active agent should be 
homogeneously dispersed in the topical preparations, 
such as by dissolving in the aqueous phase or by thor 
ough mixing with the vehicle if it does not contain an 
aqueous or polar phase. For example, a finely divided 
powder of retinoic acid glucuronide ca be dispersed in 
an oil-based vehicle such as petrolatum. 
The preparations and method of this invention are 








Synthesis of Retinoyl B-Glucuronide (Retinoic Acid 
Glucuronide) 
Retinoyl ?uoride (2.4 g, 7.9 mmol) was dissolved in 
200 ml of acetone. D-glucuronic acid (6 g, 31 mmol) 
dissolved in 50 ml of water and sodium bicarbonate (970 
mg) dissolved in 50 ml of water were added to the 
retinoyl ?uoride solution. The mixture wa stirred at 
room temperature for 20-24 hrs. The solution' was neu 
tralized with lN HCl, diluted with water, and the prod 
uct was extracted with ethyl acetate, The extract was 
washed with water, dried over anhydrous sodium sul 
fate and then evaporated to dryness in a rotary evapora 
tor. The residue was dissolved in 2-3 ml of diethyl ether 
and transferred to a silica gel (for dry column chroma 
tography, wet packed with hexane) column. The col 
umn was developed with hexane containing diethyl 
ether (5-50%) to remove retinoic acid and other prod 
ucts. The major yellow band containing retinoyl glucu 
ronide was next eluted with a mixture of 
CH2Cl2/CH3OH (1:1). The solvent was evaporated to 
dryness to give solid retinoyl B-glucuronide (2.3 g,‘ 
60%). This preparation consisted mainly of the all-trans 
isomer, and can be used as such. 
Analytically pure retinoyl B-glucuronide was ob 
tained by HPLC of the above preparation on a What 
man ODS-3 column (M9, 50 cm) using methanol/water 
(7:3) containing 10 mM ammonium acetate at a flow 
rate of 3 ml/min. Retinoyl B-glucuronide (tR,=48.7 
min) separated from traces of isomers or anomers 
(tR=46.4 min). The eluate carrying retinoyl B-glucuro 
nide was diluted with water, made just acidic with 
0.11N HCl and the product was extracted with ethyl 
acetate. The extract was washed with water, dried over 
anhydrous sodium sulfate and then evaporated to dry 
ness. The residue was dissolved in a small volume of 
diethyl ether and all-trans retinoyl B-glucuronide was 
precipitated with hexane. The solid was separatedand 
dried. All-trans retinoyl B-glucuronide: m.p. l42°-l43° 
C. (darkens at 125° C.); UVmax360 nm (1% Elm: 1065) 
in methanol and 365 nm in water. The 1H-NMR, IR and 
Mass spectra and C, H analysis results were consistent 
with the structure. The compound is soluble in water. 
Incubation of retinoyl B-glucuronide with B-glucuroni 
dase (from E. coli) in phosphate buffer (pH 6.8) for 0.5-2 
hrs generated retinoic acid. 
EXAMPLE II 
Preparation of Retinoic Acid Glucuronide Cream 
Fifty mg of ?nely powdered all-trans retinoic acid 
glucurom'de (retinoyl B-glucuronide) was dissolved in 2 
g of glycerol by agitating the mixture for several min 
utes. A commercial lotion (Nivea) (48 g) was added to 
the solution to bring the concentration of the retinoid to 
0.1%. The mixture was stirred well and stored pro 
tected from light and heat. Nivea moisturizing lotion is 
manufactured by Beiersdorf, Inc., Norwalk, Conn.), 
and is composed of water, mineral oil, glycerin, isopro 
pyl palmitate, glyceryl stearate, ceteryl alcohol, isopro 
pyl myristate, fragrance, acrylamide/sodium 'acrylate 
copolymer, lanolin alcohol, simethicon, methy 
chloroisothiazolinone and methylisothiazolinone. 
Another preparation was made in the same way add 
ing 125 mg of the retinoid to 3 g of glycerol and 47 g of 
the Nivea lotion to give a concentration of 0.25%. 
5,075,340 
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For comparison a retinoic acid cream was prepared 
as follows: 50 mg of solid all-trans retinoic acid was 
dissolved in glycerol (2 g) and mixed with 48 g of Nivea 
cream to give a concentration of 0.1%. 
EXAMPLE III 
Preparation of Retinoic Acid Glucuronide Lotion 
Fifty mg of ?nely powdered retinoic acid glucuron 
ide was dissolved in 10 g of glycerol by agitating for 
several minutes. The solution was diluted with 4-0 ml of 
water to give a 0.1% lotion of retinoid glucuronide. 
EXAMPLE IV 
Treatment of Face for Acne 
- 
l 
A female volunteer with facial acne applied the 0.1% 
retinoic acid glucuronide preparation of Example II on 
her right face, and 0.1% retinoic acid cream of Example 
11 on her left face every night before going to bed. 
Within two weeks, the left side (retinoic acid treat 
ment) became tender and red, and peeling of skin oc 
curred. Facial washing and application of make-up be 
came extremely painful. The burning and degree of 
discomfort forced her to discontinue the treatment with 
retinoic acid. 
The right side of the face (glucuronide treatment) did 
not show any sign of the above problems, although at 
the beginning the eyelids were highly sensitive to the 
cream, which sensitivity disappeared within a few days. 
After a month of the glucuronide treatment, the face 
was clear and smooth with no visible blemishes. 
Application of the 0.25% glucuronide preparation of 
Example V on the volunteer’s face did not result in any 
burning or peeling or other discomfort. 
Another female volunteer with facial acne is being 
treated with the 0.1% glucuronide preparation of Ex 
ample V. A marked degree of progress has been ob 
served in three'weeks. No burning or peeling of skin or 
other discomforts have been noted. 
EXAMPLE V 
Treatment for Wrinkles 
A male volunteer with slight wrinkles around his eyes 
applied 0.1% lotion of the retinoic acid glucuronide 
lotion of Example VI on his face every night for over 
six months. The severity of wrinkles diminished consid 
erably. No side effects were observed or reported. 
EXAMPLE VI 
Treatment for Cracked Lips 
During the winter and dry season, when his lips were 
cracked, a male volunteer applied the 0.1% retinoic 







going to bed. The cracks disappeared with a few days of 55 
application. 
EXAMPLE VII 
Clinical Trial of Retinoic Acid Glucuronide 
This study was carried out under the supervision of a 60 
local dermatologist using human acne volunteers. 
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A cream containing all-trans retinoic acid glucuron 
ide (RAG) was prepared (0.16 wt. % RAG is the molar 
equivalent of 0.1% retinoic acid) as follows: 
All ingredients, except retinoic acid glucuronide, are 
available commercially (lCI-Atlas, Atlas Chemical Di 
vision, Wilmington, Del.). The ingredients are of cos 
metic grade. 
Part I 
Stearic acid 5% (weight/weight) 
Isopropyl myristate 2% 
Arlacel 165 5% 
Butylated hydroxytoluene 0.02% 
Part II 
Sorbo (sorbitol) 20% 
Retinoic acid glucuronide 0.l6-0.32% 
Water 67.66—67.82% 
To prepare the cream, retinoic acid glucuronide was 
dissolved in the Sorbo and water mixture by stirring, 
and then heated to 72° C. (Part II). Ingredients in Part 
I are mixed and heated to 70° C. Part I and Part II are 
mixed and stirred vigorously until setting to a cream or 
heavy lotion. The cream is then poured into tubes and 
sealed. 
The cream vwas transferred to tubes which were color 
coded (blue). “Retin A” cream (RA) (Ortho ‘Pharma 
ceutical) (0.1% retinoic acid) was purchased from a 
pharmacy and transferred to tubes which were color 
coded (red). 
Acne patients received the base cream (without the 
active ingredient, RAG) for 2 weeks. This was done in 
order to ascertain that the base cream would not cause 
adverse reaction (redness, irritation, etc.) to the skin. 
After 2 weeks, in a double blind study, one group of 10 
volunteers were supplied with the blue tubes (contain 
ing RAG), and the other group of 5 volunteers received 
the red tubes (containing RA). All the volunteers ap 
plied the cream once every night before going to bed. 
After one month, when it was found that the volunteers 
applying cream from the blue tube (0.16% RAG) did 
not show any side effects, the concentration of RAG in 
the base cream was raised for all patients to 0.24% 
(green tube) and ?nally to 0.32% (yellow-green tube) 
after another month. 
The supervising dermatologist kept records of counts 
of papulo-pustules (PP), cysts, comedones and pigmen 
tation at the beginning of the study, and during subse 
quent visits during the next 7 months. The dermatolo 
gist also recorded any changes in skin condition. Photo 
graphs of the treated skin were taken at periodic inter 
vals during the trial, and each subject was asked to 
judge the effectiveness of the treatment. 
Results 
The results of the 7-month trial are summarized in 
Tables A and B. All patients receiving either RAG or 
RA showed improvements of their skin condition rang 
ing from 30-100%. Signi?cantly, however, all patients 
receiving Retin A (RA) showed skin irritation side 
effects. None of the patients receiving RAG showed 
any skin irritation effects. 
TABLE A 
Clinical Trial of Retinoic Acid Glucuronide (RAG) on Human Acne Volunteers 
Initial Counts Final Counts Total Counts Physician 
Volunteers’:I PP 8: Cysts Comedones PP 8: Cysts Comedones Before After % Improvement Evaluation Irritation 




Clinical Trial of Retinoic Acid Glucuronide (RAG) on Human Acne Volunteers 
Initial Counts Final Counts Total Counts Physician 
Volunteers” PP & Cysts Comedones PP & Cysts Comedones Before After % Improvement Evaluation Irritation 
2-JCY 6 8 2 2 l4 4 71 Good to none 
Excellent 
3‘RO 12 43 0 4 55 4 93 Excellent none 
4-RR 7 ll 0 O 18 0 100 Excellent none 
5-KT 5 16 6 8 21 14 33 Fair none 
6-PS 24 25 7 4 49 11 78 Good to none 
Excellent 
7-TM 10 6 4 5 l6 9 44 Good none 
S-JF 6 9 0 0 15 0 100 Excellent none 
9-KH 23 15 0 3‘ 38 3 92 Good to none 
Excellent 
IO-MB 15 29 5 17 44 22 51 RAG better none on 
at side)!’ than 0.025 right 
Retin~A side 
TOTAL 306 80 74% 
MEAN 30.6 8 
INine volunteers used the RAG cream, applied to both sides of the face. 
l'Volunteer MB used RAG cream only on the right side of the face. 
‘Volunteer JF discontinued before the study was completed. 
TABLE B 
Comparative Clinical Trial of Retin-A on Human Acne Volunteers 
Initial Counts Final Counts Total Counts Physician 
Volunteers‘z PP & Cysts Comedones PP & Cysts Comedones Before After % Improvement Evaluation Irritation 
ll-JG 25 10 4 6 35 10 71 Very Good all patients 
reported the 
12-MC 23 13 I3 9 36 22 39 Mild to following: 
Fair redness, 
burning, 
l3-KS 32 8 6 2 40 8 80 Excellent peeling, 
itching, 
14-] S 17 83 6 2 100 8 92 Excellent extreme dryness 
IO—MB 10 16 9 9 26 18 30 Not as observed on 
(L side)b good as left side 
RAG (R 
side) 
TOTAL 237 66 72% 
MEAN 47.4 13.2 
‘Four volunteers used the Retin-A applied to both side of the face. 
‘Volunteer MB used Retin-A only on the left side of the face. 
We claim: 
1. The method of treating human skin with a prepara 
tion in which a retinoid compound is applied to the skin 
in a topical carrier, wherein the improvement compris 
ing utilizing in said preparation as said retinoid com 
pound an effective amount of retinoic acid glucuronide 
(RAG) which effective amount is non-irritating to the 
skin. 
2. The method of treating acne on human skin while 
avoiding the side effect of retinoid dermatitis, compris 
ing applying a topical medicament to the acne afflicted 
area of a human patient’s skin, said topical 
medicament comprising an effective amount of reti 
noic acid glucuronide (RAG) in admixture with an 
emollient carrier having a liquid phase, said RAG 
being in all-trans or 13-cis form and being dissolved 
in the liquid phase of said carrier. 
3. The method of claim 2 in which the liquid phase is 
an aqueous phase. 
4. The method of claims 1, 2 or 3 in which said RAG 
is in all-trans form and is present in an amount from 
about 0.05 to 0.35 weight percent. 
5. A method of treating aging human skin with a 
retinoid compound while avoiding the side effect of 
retinoid dermatitis, comprising applying to wrinkled 
skin areas a topical medicament comprising an effective 
amount of retinoic acid glucuronide (RAG) in admix 
45 
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ture with an emollient carrier having a liquid phase, said 
RAG being all-trans or 13-cis form and being dissolved 
in said liquid phase. 
6. The method of claim Sin which said liquid phase is 
an aqueous phase. 
7. The method of claim 5 or 6 in which said RAG is 
in all-trans form and is present in an amount from about 
0.05 to 0.35 weight percent. 
8. The method of claims 2 or 5 in which said carrier 
is an ointment. 
9. The method of claims 2 or 5 in which said carrier 
is a lotion. 
10. A non-irritating topical medicament for treatment 
of human skin, comprising a composition in the form of 
an ointment or lotion containing an effective amount of 
retinoic acid glucuronide (RAG) in an emollient car 
rier, said carrier having a liquid phase in which said 
RAG is dissolved and said RAG being in all-trans or 
13-cis form. 
11. The topical medicament of claim 10 in which said 
RAG is present in said composition in an amount of 
from about 0.05 to 0.35 weight percent. 
12. The topical medicament of claim 10 in which said 
liquid phase is an aqueous phase. 
13. The topical medicament of claims 10, 11 or 12 in 
which said RAD is in all-trans form. 
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Column 3, line 48, delete "ca" and insert ——can——. 
Column 3,'line 65, delete "ca" and insert ——can——. 
Column 4, line 9, delete "we" and insert ——was——. 
Column 4, line 35, delete "0.11" and insert ——0.1——. 
Column 8, line 66, delete "RAD" and insert —-RAG——. 
Signed and Sealed {his 
Fourth Day of May, 1993 
Arrest: 
MICHAEL K. KIRK 
AfteSling Officer Acting Commissioner of Parents and Trademarks 
